NASDAQ · PHARMACEUTICAL PREPARATIONS
Celularity Inc. CELU
7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$26.6M
▼ 51.0% vs FY2024
EPS · FY25
$-3.59
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-345.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 26.6M
Revenue, FY2025 · full 7-year series below
Revenue
Net income
The company lost 345 cents on every revenue dollar this year.
Per share
USD -3.59
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-230.9%
Net margin-345.4%
Return on assets-76.4%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+13.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+13.9%
+13.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.03B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 107.3M
total assets, end of FY2025
Total assetsUSD 107.3M
EquityUSD -38.1M
CashUSD 6.2M
Gross debtUSD 33.8M
Net debtUSD 27.6M
Current ratio0.15×
Net debt stands at -73% of equity.
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
0.0
0.1
0.0
0.0
0.0
0.0
·
Operating income $B
−0.1
−0.0
−0.2
−0.0
−0.1
−0.2
−0.0
EBITDA $B
−0.1
−0.0
−0.2
−0.0
−0.1
−0.1
·
Income tax $B
0.0
·
0.0
0.0
0.0
−0.0
0.0
Net income $B
−0.1
−0.1
−0.2
0.0
−0.1
−0.2
0.0
EPS, diluted $
−3.59
−2.64
−11.02
0.95
−1.49
−11.31
0.10
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
·
−232.5
−163.7
9.5
·
·
·
Shares out B
0.03
0.02
0.02
0.01
0.12
0.02
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
21 of 21
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed